Houston Business Journal, January 24, 2007

Bayer reaches settlement over drug disclosure

Bayer Corp. will pay $8 million to 30 states, including $200,000 to Texas, as part of a settlement requiring the company to fully disclose when drugs pose risks for patients with specific health conditions. According to the settlement, Bayer failed to adequately warn physicians, pharmacies and patients of clinical studies revealing serious consequences of taking Baycol, a cholesterol-lowering drug. The company pulled the drug from the market in August 2001 due to its muscle-weakening side effects. The terms also extend to the disclosure of clinical studies involving other Bayer drugs with possibly harmful side effects.

"Texans deserve to be fully informed about the adverse effects of their medications," said Texas Attorney General Greg Abbott. "This agreement ensures that patients have access to the information they need to make educated health care decisions." The terms of the judgment require that Bayer register its clinical studies and, upon the completion of each study, post the results on the Internet. The marketing, sale and promotion of Bayer's pharmaceutical and biological products must comply with the law and cannot include false or misleading claims.

In 1997, the U.S. Food and Drug Administration approved Baycol, a "statin" cholesterol-lowering prescription drug, which Bayer began marketing in May 1998. While patients who take statin drugs frequently experience muscle-weakening side effects, Bayer failed to disclose that its product posed significantly greater risks than did statins produced by other drug companies. Because of Bayer's failure to disclose risks exacerbated by its product, patients who were prescribed Baycol were not informed of its potential side effects. Concealing risks in the name of profit violates the Texas Deceptive Trade Practices Act.
Bayer Corp. USA is a subsidiary of Bayer AG, part of the Bayer Group of companies based in Germany. The company has facilities across the U.S., including Channelview and Baytown.

more information:
· NY Times: Bayer Knew of Dangers of Its Cholesterol Drug www.cbgnetwork.org/386.html
· Bayer Held Back on Drug Dangers: www.cbgnetwork.org/288.html
· LA Times: Aspirin Can't Cure Bayer's Aches www.cbgnetwork.org/506.html

Coalition against BAYER Dangers
www.CBGnetwork.org
 CBGnetwork@aol.com
Tel: (+49) 211-333 911 Fax: (+49) 211-333 940
please send an e-mail for receiving the English newsletter Keycode BAYER free of charge

Advisory Board
Prof. Juergen Junginger, designer, Krefeld,
Prof. Dr. Juergen Rochlitz, chemist, former member of the Bundestag, Burgwald
Wolfram Esche, attorney, Cologne
Dr. Sigrid Müller, pharmacologist, Bremen
Eva Bulling-Schroeter, member of the Bundestag, Berlin
Prof. Dr. Anton Schneider, biologist, Neubeuern
Dorothee Sölle, theologian, Hamburg (died 2003)
Dr. Janis Schmelzer, historian, Berlin
Dr. Erika Abczynski, pediatrician, Dormagen

Please help us. Our international campaigns are expensive to run. We receive no public support and depend entirely on your donations.

Please send checks to:
CBG, Postfach 15 04 18, 40081 Duesseldorf, Germany

or by bank transfer to bank account number 8016 533 000 at GLS Bank, Germany
sort code: 430 609 67

BIC/SWIFT Code: GENODEM1GLS
(Bank Identifier Code)

IBAN: DE88 4306 0967 8016 5330 00
(International Bank Account Number)

Please note that bank transfers within Europe are usually no more costly than within your own country, if you quote the BIC and IBAN numbers

You may also support us online